<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02355236</url>
  </required_header>
  <id_info>
    <org_study_id>Naxozol_P4_1</org_study_id>
    <nct_id>NCT02355236</nct_id>
  </id_info>
  <brief_title>Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis</brief_title>
  <official_title>A Prospective, Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center, Interventional Study to Compare Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Severance Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Naxozol is a combination product of naproxen, a non-steroidal anti-inflammatory drug (NSAID)
      and esomeprazole, a proton pump inhibitor which is designed to improve symptoms and reduce
      risk of gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers in
      the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The
      purpose of this study is to investigate whether naxozol protects the gastrointestinal tract
      effectively compared to celecoxib, a COX-2 inhibitor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 10 orthopedic investigators will participate in this study. The effectiveness in
      gastro-protection of study drug will be assessed by Leeds Dyspepsia Questionnaire (LDQ). The
      orthopedic investigators will be trained with this questionnaire administration by an expert
      gastroenterologist prior to starting this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Leads Dyspepsia Questionnaire (LDQ) Change</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Mean change from baseline of Leads Dyspepsia Questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean LDQ</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Mean value of Leads Dyspepsia Questionnaire at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Symptom Rating Scale (GSRS) Change</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Mean change from baseline of Gastrointestinal Symptom Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Adverse Events Rate</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Dyspepsia, Diarrhoea, Nausea, Abdominal Pain, Heartburn</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Discontinuation Rate Due to Gastrointestinal Adverse Events</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief Effect, mean change from baseline of Pain Visual Analogue Scale (VAS)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Mean change from baseline of Pain Visual Analogue Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Change, mean change from baseline of EQ-5D</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Mean change from baseline of EQ-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Compliance</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Non-compliance is defined less than 80%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Drugs Usage</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Acetaminophen ER 650mg and/or Almagate 500mg will be administrated for control of severe pain events and/or of severe gastrointestinal events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Adverse Events and Abnormalities from Vital Signs, Physical Exam, and Clinical Laboratories</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Test Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naproxen/Esomeprazol 500/20mg and Comparator-Placebo for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Celecoxib 200mg and Naxozol-Placebo for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen/Esomeprazol 500/20mg</intervention_name>
    <description>Tablet, b.i.d.</description>
    <arm_group_label>Test Group</arm_group_label>
    <other_name>Naxozol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib 200mg</intervention_name>
    <description>Capsule, o.d.</description>
    <arm_group_label>Comparator Group</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naxozol-Placebo</intervention_name>
    <description>Tablet (which is identical to Naxozol), b.i.d.</description>
    <arm_group_label>Comparator Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator-Placebo</intervention_name>
    <description>Capsule (which is identical to Celebrex), o.d.</description>
    <arm_group_label>Test Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Koreans given informed consent

          -  Patients who have ability of reading comprehension and completing questionnaires
             (EQ-5D and VAS)and have willingness to follow-up 12 weeks

          -  Patients with osteoarthritis symptoms confirmed by his/her medical history and with
             pain-VAS of 40 and more

        Exclusion Criteria:

          -  Patients who participate into other interventional study or had participated within 30
             days before screening

          -  Alcohol or drug abuse within 6 months or alcohol consumption of 21 units and more in a
             week

          -  Peptic ulcers accompanied with a complication such as bleeding, perforation,
             penetration or gastric outlet obstruction within 5 years, or a history of active
             peptic ulcer or peptic ulcer without a complication within 6 months at screening

          -  Patients who are known with Helicobacter pylori infection but have not received any
             bacteriostatic treatment

          -  Known gastroesophageal reflux disease (GERD)

          -  Any following joint diseases which may significant effect to the efficacy and safety
             assessments: septic arthritis, inflammatory joint arthritis such as rheumatoid
             arthritis, gout, recurrent pseudo-pain, Paget's disease, joint fracture, joint
             ochronosis, acromegaly, hematochromatosis, Wilson's disease, primary osteochondrosis,
             Ehlers Danlos Syndrome, or other collagen genetic disorder

          -  Patients who are scheduled admissions to hospital for elective surgery during this
             study

          -  History of gastrointestinal cancer

          -  Gastrointestinal disorders related to drug malabsorption

          -  Gastrointestinal bleeding, cerebral bleeding, other bleeding disorders, or severe
             hematological disorders

          -  Clinically significant diseases such as moderate or severe liver diseases (Child Pough
             Class II or more), severe heart failure or a history of coronary artery bypass graft
             (CABG), severe kidney diseases (CrCl&lt;30ml/min)

          -  Know allergy experiences with any ingredient of study drugs or with other NASIDs or
             protocol pump inhibitors (PPIs)

          -  Patients who had had a joint surgery for osteoarthritis within 1 year

          -  Women of childbearing potential who do not agree with clinically appropriate
             contraception during this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seong-Hwan Moon, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seong-Hwan Moon, M.D., Ph.D.</last_name>
    <phone>82 2 2228 5670</phone>
    <email>shmoon@yuhs.ac</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ji-Hye Kim</last_name>
    <phone>82 2 2228 2824</phone>
    <email>CORN@yuhs.ac</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hallym University Medical Center</name>
      <address>
        <city>Anyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Moon-Soo Park, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Goyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jin-Hwan Kim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ho-Joong Kim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ho-Seong Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sang-Jin Shin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Woo-Suk Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanyang University Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Chang-Nam Kang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sang-Hoon Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Young-Hoon Kim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Seong-Hwan Moon, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>February 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2015</study_first_posted>
  <last_update_submitted>March 20, 2015</last_update_submitted>
  <last_update_submitted_qc>March 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Severance Hospital</investigator_affiliation>
    <investigator_full_name>Seong-Hwan Moon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Naxozol</keyword>
  <keyword>LDQ</keyword>
  <keyword>GSRS</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>Gastroprotective</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

